Provectus makes Alfred Smith board member
This article was originally published in Scrip
Executive Summary
Provectus Pharmaceuticals, a development stage oncology and dermatology biopharmaceutical company, has appointed Alfred Smith to its board of directors. Mr Smith is currently a senior advisor for the Marwood Group, Next Health and K2 Global Consulting. He was previously senior managing director at Bear Wagner Specialists.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.